Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.

Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG.

Invest New Drugs. 2007 Apr;25(2):131-8. Epub 2006 Oct 20.

PMID:
17053987
[PubMed - indexed for MEDLINE]
2.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC.

Clin Cancer Res. 2001 Oct;7(10):3047-55.

PMID:
11595694
[PubMed - indexed for MEDLINE]
Free Article
3.

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA.

Clin Cancer Res. 2001 Aug;7(8):2292-300.

PMID:
11489804
[PubMed - indexed for MEDLINE]
Free Article
4.

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.

Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.

Eur J Haematol. 2008 Sep;81(3):170-6. doi: 10.1111/j.1600-0609.2008.01102.x. Epub 2008 May 27.

PMID:
18510700
[PubMed - indexed for MEDLINE]
5.

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH.

Clin Cancer Res. 1997 Jan;3(1):39-46.

PMID:
9815535
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase I study of phenylacetate administered twice daily to patients with cancer.

Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE.

Cancer. 1995 Jun 15;75(12):2932-8.

PMID:
7773944
[PubMed - indexed for MEDLINE]
7.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.

Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652.

PMID:
18483378
[PubMed - indexed for MEDLINE]
Free Article
8.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.

Invest New Drugs. 2006 Jul;24(4):327-33.

PMID:
16502355
[PubMed - indexed for MEDLINE]
9.

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G; National Cancer Institute of Canada Clinical Trials Group.

Ann Oncol. 2006 Sep;17(9):1371-8.

PMID:
16966366
[PubMed - indexed for MEDLINE]
Free Article
10.

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW.

J Clin Oncol. 2008 Jan 20;26(3):361-7. doi: 10.1200/JCO.2007.12.0345.

PMID:
18202410
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.

J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.

PMID:
19636022
[PubMed - indexed for MEDLINE]
Free Article
12.

A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.

Salazar R, Bissett D, Twelves C, Breimer L, DeMario M, Campbell S, Zhi J, Ritland S, Cassidy J.

Clin Cancer Res. 2004 Jul 1;10(13):4374-82.

PMID:
15240525
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.

Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR.

J Thorac Oncol. 2007 Dec;2(12):1112-6.

PMID:
18090584
[PubMed - indexed for MEDLINE]
14.

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, et al.

Cancer Res. 1994 Apr 1;54(7):1690-4.

PMID:
8137283
[PubMed - indexed for MEDLINE]
Free Article
15.

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM.

Invest New Drugs. 2008 Feb;26(1):59-65. Epub 2007 Oct 16.

PMID:
17938863
[PubMed - indexed for MEDLINE]
16.

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.

Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T.

Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8. Epub 2007 Jun 27.

PMID:
17594093
[PubMed - indexed for MEDLINE]
17.

Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.

Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM.

Clin Cancer Res. 2008 Feb 15;14(4):1116-23. doi: 10.1158/1078-0432.CCR-07-4366.

PMID:
18281545
[PubMed - indexed for MEDLINE]
Free Article
18.

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR.

Invest New Drugs. 2008 Feb;26(1):45-51. Epub 2007 Oct 9.

PMID:
17924057
[PubMed - indexed for MEDLINE]
19.

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M.

J Clin Oncol. 2009 Apr 1;27(10):1660-6. doi: 10.1200/JCO.2008.19.5677. Epub 2009 Feb 23.

PMID:
19237630
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.

Garland L, Gitlitz B, Ebbinghaus S, Pan H, de Haan H, Puri RK, Von Hoff D, Figlin R.

J Immunother. 2005 Jul-Aug;28(4):376-81.

PMID:
16000956
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk